ArticleArchives of virology2025
The mechanism of action of micafungin against pteropine orthoreovirus infection in the human A549 cell line.
Article in Archives of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pteropine orthoreovirus (PRV) is a fusogenic virus carried by bats that causes respiratory illnesses in humans. Micafungin (MCFG), an approved drug for treatment of fungal infections, has been shown to inhibit the propagation of PRV, but its precise mechanism of action remains unclear. In this study, we investigated the molecular mechanism of action of MCFG against PRV propagation. A molecular docking simulation showed that the p17 protein of PRV is likely to be the primary target of MCFG. Differential gene expression analysis was performed to compare MCFG-treated PRV-infected host cells with untreated infected cells, and IL-6 was found to be the main regulator induced by MCFG. Silencing of IL-6 using siRNA resulted in markedly increased levels of PRV release and syncytium formation and marginally increased PRV RNA replication. Treatment with an antibody against p17, the presumed target of MCFG, markedly reduced syncytium formation but did not influence viral RNA replication. In contrast, MCFG significantly suppressed syncytium formation and slightly reduced PRV RNA replication, and MCFG and anti-p17 antibody both increased IL-6 mRNA expression. Molecular docking analysis also suggested that MCFG might inhibit other PRV proteins, including the nonstructural replication protein σNS. In conclusion, it is likely that MCFG primarily targets p17 and modulates host immunity through IL-6, which probably interferes directly with syncytium formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.